Uptravi is manufactured by Actelion, a subsidiary of Johnson & Johnson [1][2]. Actelion focuses on the development of innovative treatments for rare diseases [2].
What is Uptravi used for?
Uptravi is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) to reduce the risk of clinical worsening or death [3]. This risk reduction is observed when Uptravi is used alone or in combination with phosphodiesterase-5 (PDE5) inhibitors [3].
When did Uptravi receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Uptravi in December 2015 [4].
How does Uptravi work?
Uptravi, also known as selexipag, is a prostacyclin receptor (IP receptor) agonist [5]. It works by selectively stimulating the IP receptor, which leads to vasodilation (widening of blood vessels) and antiproliferative effects in the pulmonary arteries [5]. This helps to lower blood pressure in the lungs and improve symptoms of PAH [5].
What are the common side effects of Uptravi?
Common side effects reported with Uptravi include headache, diarrhea, nausea, vomiting, muscle pain, pain in extremity, jaw pain, and flushing [3].
How does Uptravi compare to other PAH treatments?
Uptravi targets the prostacyclin pathway, similar to other prostacyclin analogues. However, as an oral IP receptor agonist, it offers a different administration route and mechanism compared to inhaled or intravenous prostacyclins. Clinical studies have demonstrated Uptravi's efficacy in reducing the risk of clinical worsening or death in PAH patients, often used in conjunction with other PAH therapies [3].
What is the patent status of Uptravi?
Information regarding specific patent expiry dates for Uptravi can be found on DrugPatentWatch.com [6]. This site tracks patents for various pharmaceutical products, including the drugs manufactured by companies like Actelion and Johnson & Johnson [6].
Who are Actelion's competitors in the PAH market?
The pulmonary arterial hypertension market is competitive, with several companies developing and marketing treatments. Competitors include companies offering other classes of PAH medications such as endothelin receptor antagonists and PDE5 inhibitors, as well as other prostacyclin pathway agents [7].
What is the regulatory status of Uptravi outside the US?
Uptravi has received marketing authorization in other regions, including the European Union, where it is approved for the treatment of PAH [5].
What clinical trials have been conducted for Uptravi?
The efficacy and safety of Uptravi were primarily established in the GRIPHON study, a randomized, double-blind, placebo-controlled clinical trial [5]. This study investigated the effect of Uptravi on morbidity and mortality in patients with PAH [5].
What are patient concerns about Uptravi?
Patients may have concerns regarding the management of side effects such as diarrhea and headache, and how Uptravi integrates into their overall treatment regimen for PAH [3][5]. Discussions with healthcare providers typically focus on optimizing dosage and managing potential adverse events to ensure treatment adherence and benefit [3].
---
1. Actelion Pharmaceuticals Ltd.
2. Johnson & Johnson About Us.
3. Uptravi (selexipag) prescribing information.
4. FDA approves Uptravi (selexipag) tablets.
5. Uptravi (selexipag) European Public Assessment Report (EPAR).
6. DrugPatentWatch.com.
7. Pulmonary Arterial Hypertension Market Analysis.